Generation Bio Co
NASDAQ:GBIO

Watchlist Manager
Generation Bio Co Logo
Generation Bio Co
NASDAQ:GBIO
Watchlist
Price: 1.44 USD 2.86% Market Closed
Market Cap: 96.2m USD
Have any thoughts about
Generation Bio Co?
Write Note

Generation Bio Co
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Generation Bio Co
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Generation Bio Co
NASDAQ:GBIO
Change in Working Capital
$53.5m
CAGR 3-Years
N/A
CAGR 5-Years
63%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Change in Working Capital
-$1.9B
CAGR 3-Years
-19%
CAGR 5-Years
-7%
CAGR 10-Years
-20%
Gilead Sciences Inc
NASDAQ:GILD
Change in Working Capital
$7.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Change in Working Capital
-$612m
CAGR 3-Years
30%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Working Capital
-$793.5m
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Working Capital
-$593.3m
CAGR 3-Years
28%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Generation Bio Co
Glance View

Market Cap
96.1m USD
Industry
Biotechnology

Generation Bio Co. is a genetic medicine company focused on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2020-06-12. The firm through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. The company is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. The company has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.

GBIO Intrinsic Value
1.09 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Generation Bio Co's Change in Working Capital?
Change in Working Capital
53.5m USD

Based on the financial report for Dec 31, 2023, Generation Bio Co's Change in Working Capital amounts to 53.5m USD.

What is Generation Bio Co's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
63%

Over the last year, the Change in Working Capital growth was 4 999%.

Back to Top